FDA approval makes Alzheimer’s treatment easier with subcutaneous lecanemab

Weekly autoinjector option may reduce burden of IV infusions for early Alzheimer’s patients

The FDA has approved a weekly subcutaneous (under the skin) formulation of lecanemab (Leqembi Iqlik, Eisai/Biogen) for maintenance treatment in patients with early Alzheimer’s disease.

Data show that switching from IV infusions to the autoinjector maintains clinical benefit while reducing infusion-related side effects.

Study Details:

Lecanemab, marketed a…